Cystathionine -synthase (CGS) catalyzes the first step in the transsulfuration pathway leading to the formation of cystathionine from O-succinylhomoserine and l-cysteine through a -replacement reaction. As an antibacterial drug target against Xanthomonas oryzae pv. oryzae (Xoo), CGS from Xoo (XometB) was cloned, expressed, purified and crystallized. The XometB crystal diffracted to 2.4 Å resolution and belonged to the tetragonal space group I4 1 , with unit-cell parameters a = b = 165.4, c = 241.7 Å . There were four protomers in the asymmetric unit, with a corresponding solvent content of 73.9%.
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Expression, crystallization and preliminary X-ray crystallographic analysis of cystathionine c-synthase (XometB) from Xanthomonas oryzae pv. oryzae 
Introduction
Pyridoxal 5 0 -phosphate (PLP) dependent enzymes are versatile biocatalysts that can take part in a vast array of reactions such as transamination, racemization, decarboxylation and side-chain elimination and replacement in amino-acid metabolism (Clausen et al., 1996) . For decades, PLP-dependent enzymes have been extensively studied, not only because of their functional diversity but also because of their central roles in cysteine, homocysteine and methionine metabolism, which is essential for bacterial growth (Messerschmidt et al., 2003) . One example of a PLP-dependent enzyme is cystathionine -synthase (CGS).
CGS (EC 4.2.99.9) catalyzes the first step in the transsulfuration pathway leading to the formation of cystathionine from O-succinylhomoserine and l-cysteine through a -replacement reaction. In the absence of l-cysteine, CGS can perform a -elimination reaction to produce -ketobutyrate, succinate and ammonia (Kaplan & Flavin, 1966; Flavin & Slaughter, 1967; Guggenheim & Flavin, 1968) . Moreover, CGS can catalyze a -elimination reaction as well as a -replacement and an -or -proton-exchange reaction with various substrates (Guggenheim & Flavin, 1969a,b; Posner & Flavin, 1972) . In addition, CGS is regarded as an important drug target for the development of antibacterials against Escherichia coli, Mycobacterium ulcerans and Helicobacter pylori. Structures of CGS from these organisms have been determined at atomic resolution (Clausen et al., 1998; Clifton et al., 2011; Kong et al., 2008) .
In Xanthomonas oryzae pv. oryzae (Xoo), a causal agent of bacterial blight (BB) of rice (Oryza sativa L.), CGS is encoded by the metB gene (XometB). Even though the whole genome sequence of X. oryzae pv. oryzae was determined in 2005 (Ochiai et al., 2005; Lee et al., 2005) , information on PLP-dependent enzymes in Xoo is still lacking. This study describes the cloning, expression, purification, crystallization and preliminary X-ray crystallographic studies of XometB. A three-dimensional structural study of XometB will elucidate the molecular basis for the enzymatic reaction mechanism of CGS and will be useful for the design of a potential antibacterial drug against Xoo.
Materials and methods

Cloning
The XometB gene in X. oryzae pv. oryzae encodes a total of 405 amino-acid residues. The full-length XometB gene was amplified via polymerase chain reaction using bacterial cells (Xoo KACC10331
# 2012 International Union of Crystallography All rights reserved strain) as the template. The sequences of the forward and reverse oligonucleotide primers designed from the published genome sequence (Lee et al., 2005) were as follows: 5 0 -GGG CAT ATG AGC TTT CGT GAC CCC ACC CAC ACC-3 0 and 5 0 -GGG GGA TCC TCA CGC GTC GAC TTT TTT ACG GTT-3 0 , respectively. The bases in bold designate the NdeI and BamHI digestion sites. The amplicon was double-digested with NdeI and BamHI, ligated into the pET15b expression vector (Novagen) containing a 6ÂHis tag upstream of a thrombin cleavage site, yielding the recombinant clone pET15b-XometB, and transformed into E. coli BL21 (DE3) pLysS.
Overexpression and purification
E. coli BL21 (DE3) pLysS cells containing pET15b-XometB, coding for residues 1-405, were grown at 310 K to an OD 600 of 0.6 in Luria-Bertani medium supplemented with 100 mg ml À1 ampicillin and 37 mg ml À1 chloramphenicol. Protein expression was induced by the addition of 0.5 mM IPTG. The cells were cultured at 310 K for an additional 4 h. The cells were harvested by centrifugation at 3000g (Hanil Supra 30K A1000S-4 rotor, Seoul, Republic of Korea) for 30 min at 277 K. The cell pellet was then resuspended in ice-cold lysis buffer (25 mM Tris-HCl pH 7.5, 300 mM NaCl, 15 mM imidazole, 3 mM -mercaptoethanol) and homogenized by ultrasonication on ice (Sonomasher). The crude cell extract was centrifuged for 1 h at 19 960g (Hanil) at 277 K to remove cell debris. The supernatant was applied onto Ni-NTA His-Bind resin (Novagen) and affinity purification was performed according to the manufacturer's protocol at 277 K. The column was washed using lysis buffer including 40 mM imidazole. The 6ÂHis-tagged XometB protein was then eluted using lysis buffer containing 250 mM imidazole and dialyzed against thrombin cleavage buffer (25 mM Tris-HCl pH 7.5, 15 mM NaCl, 3 mM -mercaptoethanol) for 16 h at 277 K. After dialysis, the protein was treated with 0.1 U thrombin (Sigma) per milligram of XometB for 6 h at 293 K in order to remove the N-terminal 6ÂHis tag and was again applied onto Ni-NTA His-Bind resin (Novagen) to remove any uncleaved protein. After cleavage, three additional residues (Gly-Ser-His) from the pET15b vector remained at the N-terminus of XometB. The flowthrough fraction containing cleaved XometB protein was collected and applied onto a HiTrap Q ionexchange column (GE Healthcare) for further purification. The homogeneity of the purified protein was analyzed via SDS-PAGE (Fig. 1) . For crystallization, the protein solution was concentrated using Centri-Prep (Millipore) to a final concentration of 9 mg ml À1 in a buffer consisting of 25 mM Tris-HCl pH 7.5, 15 mM NaCl, 3 mM -mercaptoethanol.
Crystallization and X-ray data collection
Before setting up the crystallization trials, XometB stock solution (9 mg ml À1 ) was incubated with 80 mM PLP for 30 min. Initial crystallization was carried out at 287 K by the sitting-drop vapourdiffusion method in 96-well Intelli-Plates (Art Robbins) using a Hydra II e-drop automated pipetting system (Matrix) and screening Purified XometB is shown on a 12% SDS-PAGE gel (lane P). Lane M contains molecular-mass markers (labelled in kDa). (Fig. 2a) . Fully grown crystals (0.4 Â 0.04 Â 0.03 mm) were flash-cooled at 100 K in liquid nitrogen using 20%(v/v) PEG 4000, 0.2 M MgCl 2 , 0.1 M HEPES pH 7.5 as a cryoprotectant. In addition, after 5 d, another well grown crystal (0.35 Â 0.15 Â 0.15 mm; crystal 2) was observed from the Intelli-Plates using condition E7 of the Morpheus screen (Molecular Dimensions; Gorrec, 2009; Fig. 2b ). Condition E7 consists of 0.12 M Ethylene Glycols Mix (di-ethyleneglycol, tri-ethyleneglycol, tetra-ethyleneglycol and penta-ethyleneglycol), 0.1 M Na HEPES/MOPS pH 7.5, 10%(w/v) PEG 4000, 20%(v/v) glycerol. This crystal was directly picked up from the drop and flash-cooled at 100 K in liquid nitrogen because this crystallization condition from the Morpheus screen is inherently cryoprotected. X-ray diffraction data were collected from the cryoprotected crystals with 1 oscillation and a crystal-to-detector distance of 300 mm using an ADSC Q315r detector on beamline 5C SBII of the Pohang Light Source (PLS), Republic of Korea. The crystals diffracted to 2.9 Å (crystal 1) and 2.4 Å (crystal 2) resolution, respectively. Diffraction data were integrated and scaled using DENZO and SCALEPACK, respectively (Otwinowski & Minor, 1997) .
Results and discussion
The XometB crystals were yellow, indicating the presence of an internal Schiff base between Lys and the PLP cofactor. Both crystals belonged to space group I4 1. The 2.4 Å resolution data set was used to determine the XometB structure. The unit-cell parameters were a = b = 165.4, c = 241.7 Å . The space group was derived by autoindexing (Otwinowski & Minor, 1997) and data-collection statistics are provided in Table 1 . According to the Matthews coefficient calculation (Matthews, 1968) , there are probably eight molecules in the asymmetric unit, corresponding to a V M of 2.35 Å 3 Da À1 and a solvent content of 47.7%. However, molecular replacement (MR) using Phaser in the CCP4 program package (McCoy et al., 2007) with cystathionine -synthase from E. coli (PDB entry 1cs1; Clausen et al., 1998; 58 .0% sequence identity) as a search model was successful and indicated the presence of four protomers in the asymmetric unit with a high solvent content of 73.9%. The initial R factor from the molecular-replacement search was 42.0%; the resulting electrondensity maps were of high quality and no clashes were found between molecules. After rigid-body and initial restrained refinement using REFMAC5 (Murshudov et al., 2011) , the R factor decreased to 27.9% and R free was 31.0%. The structure is currently being refined and the final structural details will be described in a separate paper. Our structural data for XometB will provide an insight into its enzymatic mechanism and will be useful for developing a potential antibacterial drug against Xoo. 
